Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CADL
CADL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CADL News
Candel Therapeutics Announces Public Offering Pricing
Feb 20 2026
Benzinga
U.S. Stock Futures Rise as Market Awaits GDP Data Release
Feb 20 2026
Benzinga
Candel Therapeutics Prices $100 Million Share Offering
Feb 20 2026
NASDAQ.COM
Candel Therapeutics Prices $100M Public Offering
Feb 20 2026
seekingalpha
Candel Therapeutics Prices $100 Million Public Offering
Feb 20 2026
Newsfilter
Candel Therapeutics Prices Public Offering at $5.45 per Share
Feb 20 2026
Yahoo Finance
Candel Launches $100 Million Public Offering
Feb 20 2026
stocktwits
Candel Therapeutics Announces $100M Public Offering
Feb 19 2026
seekingalpha
Candel Therapeutics to Hold Online R&D Event on December 5, 2025
Nov 17 2025
Newsfilter
Citigroup Upholds Buy Rating for Candel Therapeutics (CADL)
Nov 15 2025
NASDAQ.COM
Candel Halts Development of CAN-2409 for Prostate Cancer
Nov 14 2025
SeekingAlpha
Candel Therapeutics Announces Financial Results for Q3 2025 and Key Corporate Updates
Nov 13 2025
Newsfilter
Candel Therapeutics to Showcase at Jefferies Global Healthcare Conference in London
Nov 03 2025
Newsfilter
LifeSci Capital Begins Coverage of Candel Therapeutics with Outperform Rating and Sets Price Target at $16
Oct 21 2025
Benzinga
Candel Therapeutics to Showcase at the 2025 SITC Annual Meeting
Oct 03 2025
Newsfilter
HC Wainwright & Co. Affirms Buy Rating for Candel Therapeutics, Keeps $23 Price Target Intact
Sep 29 2025
Benzinga
Show More News
